- Biotechnology
- Tuesday, 19 May 2020
Enzychem Lifesciences Appoints Duke Medical Coronavirus Task Force Expert Dr. Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug
Enzychem Lifesciences, a global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, announced that Dr. Cameron Robert Wolfe, associate professor of medicine at Duke University School of Medicine, an internationally renowned specialist in infectious diseases, has been appointed to lead the Company's U.S COVID-19 efforts of the development of EC-18 as a COVID-19 therapeutic drug.
Dr. Wolfe has been leading Duke University Medical School's Coronavirus Task Force, where he has been on the frontlines treating COVID-19 patients.
He is a nationally recognized infectious disease expert, specializing in HIV infection, transplant-related infectious diseases, general infectious diseases, biological and emergency preparedness for hospital systems, influenza and respiratory viral pathogens. He conducted his fellowship in infectious diseases at Duke University School of Medicine, and his M.B.B.S from the University of Melbourne. He is currently an investigator on the Phase 3 study for Remdesivir (GS-5734) in severe COVID-19 participants, a Phase 3 study of Remdesivir in Moderate COVID-19 patients, the Adaptive COVID-19 Treatment Trial (ACTT), and the CARE Focus 1: Latency Biomarker Project.
"We are honored to have Dr. Wolfe, an internationally recognized expert in infectious diseases, who is currently conducting numerous research studies on COVID-19, to lead our U.S COVID-19 efforts," said Ki Young Sohn, Chairman & CEO of Enzychem Lifesciences. "With his extensive experience in COVID-19, Dr. Wolfe will be able to provide high-level guidance and counsel to our scientific team, as we prepare our lead compound, EC-18, as a potential treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19, and development plan more broadly in other infectious diseases."
"I look forward to working with Chairman Sohn and the rest of the Enzychem Lifesciences team to develop EC-18, a promising candidate with the potential to treat not only ARDS and COVID-19 related complications, but as a potential therapy for other infectious diseases. EC-18 has activity in a wide-range of indications, and I look forward to working with the team as we advance EC-18," said Dr. Wolfe.
Related Industry Updates
Asia Pacific Linear Accelerator Market 2019: Development, Growth, Key Factors And Forecast to 2027 | BEVATECH GmbH, CGN Dasheng, Elekta AB, IBA, diondo GmbH
Dec 08, 2020
Higher Investment in R&D boost Pre Clinical CROs Market in Developed Countries
Apr 20, 2020
Genetic Engineering Market to Witness Promising Growth Opportunities by 2021-2027 | Global Share, Size, Manufacturer Data, Production, Future Plans, Strategies, Deployment Model etc.
Mar 16, 2021
Intracardiac Echocardiography Market Size and Trends Study Released by Top Publisher at : Abbott oston Scientific Corporation, Koninklijke Philips N.V
Apr 06, 2021
Blood Analyzer Market Growing Demand and Growth Opportunity
May 03, 2021
Laboratory Centrifuges Market 2020-2027: Demand Analysis, Industry Size, Share, Growth Factor, Revenue, Challenges, Segments, Key Manufacturers, Globally Development, Competition Strategies and Forecast to 2027
Dec 30, 2020
Gene Editing: A Medical Breakthrough Facing Ethical Challenges
Mar 19, 2020